{"id":"W3201876104","doi":"10.1016/j.ejca.2021.08.023","title":"Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer","year":2021,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre","funders":"Medac; PharmaMar; Deutsche Krebshilfe; Eisai; European Commission; Chugai Pharmaceutical; Seagen; F. Hoffmann-La Roche; Incyte; Mersana Therapeutics; Karyopharm Therapeutics; Clovis Oncology; Deutsche Forschungsgemeinschaft; GlaxoSmithKline; Takeda Oncology; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Olaparib; Bevacizumab; Medicine; Hazard ratio; Oncology; Placebo; Internal medicine; Population; Ovarian cancer; Cancer; Confidence interval; Chemotherapy; Pathology; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002324211,0.0002283618,0.001073952,0.0001386303,0.00009718234,0.00002396307,0.0001752203,0.00004661402,0.0004037131],"category_scores_gemma":[0.00184857,0.0001019566,0.0001905864,0.0006231252,0.0001366658,0.0001489705,0.00003963466,0.0002874233,5.765446e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007710705,"about_ca_system_score_gemma":0.001160988,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003305406,"about_ca_topic_score_gemma":0.001749203,"domain_scores_codex":[0.9948795,0.002281662,0.001744897,0.0002324977,0.0006244868,0.000236995],"domain_scores_gemma":[0.995407,0.001118421,0.002361925,0.0003097536,0.0007143051,0.00008863862],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.0205631,0.0007749973,0.1700533,0.0002267725,0.001183656,0.000215848,0.01052124,0.008048126,0.0491742,0.0001280908,0.001660227,0.7374504],"study_design_scores_gemma":[0.07332344,0.002393739,0.8683776,0.006261362,0.0008359375,0.000157896,0.001591961,0.001483522,0.04202949,0.0002103625,0.003051347,0.0002833451],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9854989,0.007279042,0.0002368167,0.004985444,0.0008440989,0.0007819767,0.00008356154,0.00001022168,0.000279929],"genre_scores_gemma":[0.9946349,0.003313433,0.0004888454,0.0003152193,0.0001923477,0.00003728379,0.00000676519,0.00004223726,0.0009689563],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7371671,"threshold_uncertainty_score":0.4420376,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1338717010028006,"score_gpt":0.4275435263922756,"score_spread":0.2936718253894749,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}